Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ord Shs
(OP:
TKPHF
)
26.90
UNCHANGED
Streaming Delayed Price
Updated: 9:54 AM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ord Shs
< Previous
1
2
Next >
Current Analysis: Takeda Pharmaceutical
April 09, 2024
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of...
Via
Talk Markets
Current Analysis: Takeda Pharmaceuticals (TKPHF)
November 12, 2023
TKPHF is the largest Japanese drug company. Furthermore the estimated $45.50 dividend income from $1k invested is about 1.64 times greater than Friday’s price of a single share
Via
Talk Markets
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
May 11, 2023
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...
Via
Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
May 11, 2023
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its
Via
Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
December 13, 2022
Via
Benzinga
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
November 23, 2022
Via
Benzinga
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
October 27, 2022
Via
Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
October 05, 2022
Via
Benzinga
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
March 20, 2023
Via
Benzinga
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
February 21, 2023
Via
Benzinga
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
February 02, 2023
Via
Benzinga
Why Shares of Phathom Pharmaceutical Jumped This Week
January 28, 2023
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
Via
The Motley Fool
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
January 09, 2023
Via
Benzinga
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
November 17, 2022
Via
Benzinga
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
July 21, 2022
Via
Benzinga
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
May 11, 2022
Via
Benzinga
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
January 31, 2022
The
Via
Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
Via
Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
August 26, 2022
Via
Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
July 27, 2022
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...
Via
Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
July 01, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Via
Benzinga
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
April 22, 2022
Via
Benzinga
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
March 08, 2022
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...
Via
Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
February 22, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...
Via
Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
February 18, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...
Via
Benzinga
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
December 22, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...
Via
Benzinga
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
December 16, 2021
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd...
Via
Benzinga
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
November 24, 2021
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.